Physician profile
Mark A Wenger
NPI 1336139666
$561.48
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $89.63 · 2021: $106 · 2022: $28.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $82.72 | 2019-2022 | |
| Genzyme Corporation | $70.33 | 2019 | |
| Glaxosmithkline, LLC. | $69.35 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $64.82 | 2019-2020 | |
| Csl Behring | $63.98 | 2019-2020 | |
| Optinose US, INC. | $54.59 | 2019 | |
| Genentech USA, INC. | $37.62 | 2019 | |
| Amgen INC. | $31.07 | 2021 | |
| Covis Pharma Gmbh | $25.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.49 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.28 | 2019 | |
| Pfizer INC. | $16.24 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.